Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer
NCT ID: NCT01980849
Last Updated: 2013-11-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
272 participants
INTERVENTIONAL
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment
NCT05486650
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
NCT05615142
A Real-world Study of the Efficacy and Safety of PD-1 Inhibitors Combined With Chemoradiotherapy in Lung Metastatic Nasopharyngeal Carcinoma
NCT07062484
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer
NCT03944980
Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With Totally Implantable Access Ports
NCT04309240
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Long term prophylaxis
Nadroparin, 0.4mL, subcutaneously, qid, given by long-term
Nadroparin, long term
Short-term prophylaxis
Nadroparin, 0.4mL, subcutaneously, qid, given during hospitalization
Nadroparin: short-term
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nadroparin, long term
Nadroparin: short-term
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Performance status score ≤ 2
* Chest CT with measurable lesions
Exclusion Criteria
* Chemotherapy regimens containing bevacizumab or Endostar
* Severe coagulopathy
* Active bleeding within two weeks
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shengqing Li
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shengqing Li
Consultant, Associate professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Department of Oncology，Southwest Hospital
Chongqing, Chongqing Municipality, China
The Department of Pulmonary and Critical Care Medicine,Southwest Hospital
Chongqing, Chongqing Municipality, China
The Department of Oncology，Ohtsubo Hospital
Chongqing, Chongqing Municipality, China
The Department of Oncology，Fuling Central Hospital
Chongqing, Chongqing Municipality, China
The Department of Oncology，Central Hospital
Xinxiang, Henan, China
The Department of Oncology，People's Hospital
Zhengzhou, Henan, China
The Department of Pulmonary and Critical Care Medicine,Cancer Hospital
Zhengzhou, Henan, China
The Department of Oncology，Henan University Affiliated Yihe Hospital
Zhengzhou, Henan, China
The Department of Oncology，Cancer Hospital
Baotou, Inner Mongolia, China
The Department of Oncology，Northern Hospital
Baotou, Inner Mongolia, China
The Department of Oncology，Inner Mongolia Autonomous Region Hospital
Hohhot, Inner Mongolia, China
The Department of Pulmonary and Critical Care Medicine,Medical University General Hospital cardiovascular and cerebrovascular disease hospital
Yinchuan, Ningxia, China
The Department of Pulmonary and Critical Care Medicine,Central Hospital
Baoji, Shaanxi, China
The Department of Pulmonary and Critical Care Medicine,Second People's Hospital
Xi'an, Shaanxi, China
The Department of Pulmonary and Critical Care Medicine, Second Affiliated Hospital of Jiaotong University
Xi'an, Shaanxi, China
The Department of Pulmonary and Critical Care Medicine, Tangdu Hospital
Xi'an, Shaanxi, China
The Department of Pulmonary and Critical Care Medicine, Xijing Hospital
Xi'an, Shaanxi, China
The Department of Oncology，First Affiliated Hospital of Jiaotong University
Xi'an, Shaanxi, China
The Department of Oncology，Yan'an University Hospital
Yan’an, Shaanxi, China
The Department of Oncology，Second Hospital of Shanxi Medical University
Taiyuan, Shanxi, China
The Department of Lung oncology，Tumor Hospital
Chengdu, Sichuan, China
The Department of Oncology，People's Hospital
Chengdu, Sichuan, China
The Department of Oncology，First Affiliated Hospital of Medical University
Ürümqi, Xinjiang, China
The Department of Pulmonary and Critical Care Medicine,First Affiliated Hospital of Medical University
Ürümqi, Xinjiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Shengqing Li, MD, PhD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LCAN-20131105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.